Custom service
Peptide-Based Nucleic Acid Delivery Services
Deliver sirna, aso or mrna with peptide carriers and ligands
The service is built around electrostatic and covalent peptide–NA complexes. Depending on the molecule we may move to GalNAc and tissue-selective ligands or serum-stability test matrix to improve stability, loading or yield, and every batch is released with delivery system with knockdown or expression data.
Because Peptide-Based Nucleic Acid Deliverys projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.
Tissue-targeted oligonucleotide delivery research
Non-viral mRNA delivery concepts
GMP nucleic-acid drug product
In-vivo dosing campaigns without a completed in-vitro validation stage
Delivery programmes are released in two layers: chemical (identity, purity, payload loading) and functional (uptake, knockdown or transfection readout in the agreed cell model). Both layers are documented, because a construct that is chemically perfect but functionally silent is a failure.
Service Highlights
- electrostatic and covalent peptide–NA complexes as the default route, with GalNAc and tissue-selective ligands held as a proven fallback
- Serum-stability test matrix worked into the design where the application requires it
- Every delivery construct is validated for uptake or knockdown function, not just characterized chemically
- Analytical confirmation of every intermediate before the final release
- Serum-stability and competitive-serum conditions are part of the standard test matrix
- Delivery system with knockdown or expression data delivered with a complete conjugation or synthesis certificate
How the work runs
Payload & target review
Payload chemistry, target cell and readout are agreed; Peptide-Based Nucleic Acid Delivery Services concept routes are drafted.
Construct design
Peptide ligand, linker and presentation are designed; electrostatic and covalent peptide–NA complexes is selected.
Assembly
The construct is assembled and purified chemically, with payload loading quantified.
Functional validation
Uptake or knockdown is measured in the target cell model, with GalNAc and tissue-selective ligands controls.
Stability & optimization
Serum stability and iteration rounds tune the design to the agreed specification.
Release & hand-off
Delivery system with knockdown or expression data plus the validation report is released with a handling SOP.
Specifications & timeline
- Turnaround
- 5–9 weeks
- Typical scale
- mg-scale construct plus validation report
- Chemistry options
- electrostatic and covalent peptide–NA complexes; GalNAc and tissue-selective ligands; serum-stability test matrix
- Deliverable
- Delivery system with knockdown or expression data
- QC package
- Chemical QC plus functional uptake/delivery assay data
- Shipping
- Blue ice, aliquoted, with handling SOP
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.